TEVA(US:TEVA)2025-01-29 13:11Financial Performance & Growth - Teva's Q4 2024 revenues were $4229 million, a decrease of 5% compared to Q4 2023, but full year 2024 revenues increased by 4% to $16544 million[70] - Global generics revenue increased by 11% to $9461 million in 2024[15] - Teva API revenue increased by 3% to $553 million in 2024[9] - Free cash flow for FY 2024 was $2068 million, a decrease of 13% compared to $2387 million in FY 2023[70] - The company is targeting mid-single digit percentage revenue growth (CAGR) from 2023-2027[11] Key Products Performance - AUSTEDO U S revenues increased by 34% compared to 2023, reaching $1642 million[9, 18] - UZEDY revenues reached $117 million in 2024, exceeding the outlook of approximately $100 million[9, 20] - AJOVY global revenues in Q4 2024 were $142 million, representing an 18% growth[24, 25] Pipeline & Innovation - Duvakitug (anti-TL1A) Phase II trial showed positive results, with Phase III initiation targeted for 2025[9, 28] - Olanzapine LAI completed targeted injections in Phase III with no Post-Injection Delirium/Sedation Syndrome (PDSS), with long-term study full safety presentation expected in H1 2025[9, 28] - DARI (ICS/SABA) Phase III clinical trial sites activation exceeded 91%[9] Financial Health - Gross debt decreased to $178 billion as of December 31, 2024[74, 125] - Net debt decreased to $145 billion as of December 31, 2024[74, 125]